Remediation of Emotional Processing Deficits in MS
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology, Neurology, Multiple Sclerosis |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 12/16/2017 |
| Start Date: | November 2016 |
| End Date: | December 2019 |
| Contact: | Angela A Smith, MA |
| Email: | asmith@kesslerfoundation.org |
| Phone: | 973-324-8448 |
Remediation of Emotional Processing Deficits in MS: A Randomized Clinical Trial
This study will test the effectiveness of an emotional processing intervention in individuals
with MS in a double blind placebo controlled randomized clinical trial. We will utilize an
intervention which has been successfully used in other populations, including Schizophrenia
and Traumatic Brain Injury. Our pilot data shows that this intervention is effective in
individuals with MS as well
with MS in a double blind placebo controlled randomized clinical trial. We will utilize an
intervention which has been successfully used in other populations, including Schizophrenia
and Traumatic Brain Injury. Our pilot data shows that this intervention is effective in
individuals with MS as well
This study will test the effectiveness of an emotional processing intervention in individuals
with MS in a double blind placebo controlled randomized clinical trial RCT). We will utilize
an intervention which has been successfully used in other populations, including
Schizophrenia and Traumatic Brain Injury. Our pilot data shows that this intervention is
effective in individuals with MS, as well.
All participants will undergo a baseline evaluation assessing emotional processing abilities,
cognitive functioning, and psychological functioning. Participants will then be randomized
into two groups. During the treatment phase, the experimental group will receive the proposed
intervention while the control group will receive a "placebo" treatment. Neuropsychological
assessment will be repeated at the end of the intervention.
with MS in a double blind placebo controlled randomized clinical trial RCT). We will utilize
an intervention which has been successfully used in other populations, including
Schizophrenia and Traumatic Brain Injury. Our pilot data shows that this intervention is
effective in individuals with MS, as well.
All participants will undergo a baseline evaluation assessing emotional processing abilities,
cognitive functioning, and psychological functioning. Participants will then be randomized
into two groups. During the treatment phase, the experimental group will receive the proposed
intervention while the control group will receive a "placebo" treatment. Neuropsychological
assessment will be repeated at the end of the intervention.
Inclusion Criteria:
- between the ages of 18-65.
- diagnosis of Relapsing-Remitting Multiple Sclerosis.
- can read and speak English fluently.
Exclusion Criteria:
- history of prior stroke or other neurological disease or injury.
- history of significant psychiatric illness (for example, bipolar disorder,
schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder,
Schizophrenia, Epilepsy, Bipolar Disorder.
- significant alcohol or drug abuse history.
We found this trial at
1
site
Click here to add this to my saved trials
